Laurence Blumberg, Arch Oncology CEO (Arch)
Arch Oncology thinks it can stand out in the red-hot CD47 field, and it's taking $105M in new cash to prove it
In the past few years, a spate of companies have jumped into the search for a cancer therapy that blocks CD47’s “don’t eat me” signal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
